Search company, investor...
Biosplice Therapeutics company logo

Biosplice Therapeutics

biosplice.com

Executives

13

Biosplice Therapeutics Management Team

13 Team Members

Biosplice Therapeutics has 13 executives. Biosplice Therapeutics's current Founder, Chief Executive Officer is Osman Kibar.

Name

Work History

Title

Status

Osman Kibar

Founder, Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Osman Kibar

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

This profile has not been claimed.

Highlight your management team’s expertise.

Compare Biosplice Therapeutics to Competitors

L
Lubris BioPharma

Lubris BioPharma is a development-stage life science company producing and commercializing a recombinant version of the human protein, lubricin. Lubricin is expressed in numerous parts of the human body and plays an important role in protecting surfaces from damage and wear. Opinion leaders and clinicians worldwide are focusing their research efforts on using lubricin to improve the lives of millions of people with a host of unmet medical needs including dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis.

Oyster Point Pharma Logo
Oyster Point Pharma

Oyster Point Pharma (NASDAQ: OYST) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies to treat diseases with high unmet needs. The company's initial focus is to develop therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. The company was founded in 2015 and is based in Princeton, New Jersey.

Aldeyra Therapeutics Logo
Aldeyra Therapeutics

Aldeyra Therapeutics, formerly Neuron Systems, is a biotechnology company focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The company discovered and is developing NS2, a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of Sjogren-Larsson Syndrome (SLS), a rare disease caused by mutations in an enzyme that metabolizes fatty aldehydes, and acute anterior uveitis, an inflammatory eye disease.

Bioventus Logo
Bioventus

Bioventus (NASDAQ: BVS) is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.